-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, I1kxKcqGhWxB4jLtpuwuFGWpHkZuYAWoNMWQ7ydJJe1maaYSRy+77/l56KeuRCmJ HPYeTz8uySHzP/axopL4Rw== 0000950005-97-000307.txt : 19970307 0000950005-97-000307.hdr.sgml : 19970307 ACCESSION NUMBER: 0000950005-97-000307 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19970306 SROS: NONE SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: LYNX THERAPEUTICS INC CENTRAL INDEX KEY: 0000913275 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 943161073 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-45671 FILM NUMBER: 97551912 BUSINESS ADDRESS: STREET 1: 3832 BAY CENTER PL CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 5106709300 MAIL ADDRESS: STREET 1: 3832 BAY CENTER PLACE CITY: HAYWARD STATE: CA ZIP: 74545 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BRENNER SYDNEY CENTRAL INDEX KEY: 0001034838 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 3832 BAY CENTER PL CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 5106709300 MAIL ADDRESS: STREET 1: 3832 BAY CENTER PLACE CITY: HAYWARD STATE: CA ZIP: 74545 SC 13D 1 SCHEDULE 13D - ---------------------------------- OMB APPROVAL - ---------------------------------- OMB Number: 3235-0145 Expires: December 31, 1997 Estimated average burden hours per response........14.90 - ---------------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ______)* Sydney Brenner, M.B., D. Phil. ------------------------------ (Name of Issuer) Common Stock ------------------------------ (Title of Class of Securities) 551812 30 8 ------------------------------ (CUSIP Number) If filing person has previously filed a statement of Schedule 13G to report the acquisition which is the subject of this Schedule 13D and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following |_|. Check the following box if a fee is being paid with this statement |X|. (A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7). *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 4 pages - ---------------------------------- ----------------------- CUSIP No. 551812 30 8 13D Page 2 of 4 Pages ------------------------- - ---------------------------------- ----------------------- - --------- ---------------------------------------------------------------------- 1 NAME OF REPORTING PERSONS S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS Sydney Brenner, M.B., D. Phil. ###-##-#### - --------- ---------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_| (b) |_| - --------- --------------------------------------------------------------------- 3 SEC USE ONLY - --------- ---------------------------------------------------------------------- 4 SOURCE OF FUNDS* see Item 3 - --------- -------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) pr 2(e) |_| - --------- -------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION British citizen - -------------------------- --------- ------------------------------------------- 7 SOLE VOTING POWER 275,375(1) NUMBER OF --------- ------------------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 0 OWNED BY EACH --------- ------------------------------------------ REPORTING 9 SOLE DISPOSITIVE POWER PERSON WITH 275,375(1) --------- ------------------------------------------- 10 SHARED DISPOSITIVE POWER 0 - -------------------------- --------- ------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 275,375(1) - --------- ---------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* |_| - --------- ---------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 8.7% - --------- ---------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* IN - --------- ---------------------------------------------------------------------- - -------- (1) Includes 15,375 shares of Common Stock issuable upon exercise of Lynx stock options held by Dr. Brenner that are exercisable within 60 days of February 28, 1997. Page 2 of 4 pages Item 1. SECURITY AND ISSUER (a) Name of Issuer: Lynx Therapeutics, Inc. (b) Address of Issuer's Principal Executive Offices: 3832 Bay Center Place Hayward, CA 94545 Item 2. IDENTITY AND BACKGROUND (a) Name of Person Filing: Sydney Brenner, M.B. Phil. Director (b) Address of Principal Business Office or, if None, Residence: 3832 Bay Center Place Hayward, CA 94545 (c) Citizenship: British (d) Title of Class of Securities: COMMON (e) CUSIP Number: 551812 30 8 Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATIONS On November 4, 1996, Lynx and its subsidiary, Spectragen, Inc., merged pursuant to a Merger Agreement between the Company and the Spectragen employees, dated October 23, 1996. Prior to the merger, Dr. Brenner, director of Spectragen, was issued two hundred thousand (200,000) shares of Spectragen's Common Stock for his technology and patent contributions. Upon consummation and pursuant to the merger, the Reporting Person received 260,000 shares of Lynx Common Stock. The conversion rate was 1:1.3. The shares, beneficially owned by the Reporting Person also includes 15,375 shares exercisable, within 60 days of February 28, 1997. Item 4. PURPOSE OF TRANSACTION See Item 3 (above) Page 3 of 4 pages Item 5. INTEREST IN SECURITIES OF ISSUER The following table sets forth certain information on the beneficial ownership of Issuer's common stock by the Reporting Person. The percentage set forth in the table reflects 3,152,148 shares outstanding. (a) Beneficial Ownership: 275,375(1) (b) Percentage Ownership: 8.7% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 275,375(1) (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 275,375(1) (iv) shared power to dispose or to direct the disposition of: 0 Instruction. For computations regarding securities which represent a right to acquire an underlying security, see Rule 13d-3(d)(1). Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER none Item 7. EXHIBITS none SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. March 5, 1997 ----------------- Date LYNX THERAPEUTICS, INC. BY: /s/ Sydney Brenner --------------------------------------- Sydney Brenner, M.B. Phil. Director Page 4 of 4 pages -----END PRIVACY-ENHANCED MESSAGE-----